Albucult will be the key component in the treatment for dry eye syndrome
R-Tech Ueno has chosen Novozymes Biopharma’s Albucult recombinant human albumin for use in a treatment for dry eye syndrome.
The Japan-based global specialist in ophthalmology and dermatology treatments will use Albucult as a key component in its new therapy, which will be the first of its kind for the treatment of severe and moderate dry eye conditions.
Albucult is manufactured by Novozymes’ long-term technology partner, Kaketsuken, based in Kumamoto, Japan and marketed by Novozymes worldwide.
The prevalence of dry eye syndrome continues to increase, with the condition having the highest rate of diagnosis of all ophthalmic disorders. Novozymes says Albucult confers a number of benefits to the development of R-Tech Ueno’s new therapy, including an exceptional purity profile and batch-to-batch consistency.